Chronic Obstructive Pulmonary Disease, COPD VT014(PM014)


Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult. Chronic bronchitis and emphysema are older terms used for different types of COPD. The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.

Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires. Long-term exposure to these irritants causes an inflammatory response in the lungs, resulting in narrowing of the small airways and breakdown of lung tissue. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.

Most cases of COPD can be prevented by reducing exposure to risk factors. This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, no cure is known. COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.


As of 2015, COPD affected about 174.5 million (2.4%) of the global population. It typically occurs in people over the age of 40. Males and females are affected equally commonly. In 2015, it resulted in 3.2 million deaths, up from 2.4 million deaths in 1990. More than 90% of these deaths occur in the developing world. The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.


The Development of Candidate Materials for "Chungsangboha-tang", a herbal medicine that has been proven to be effective as a result of the Korean herbal medicine treatment technology project for 4 years.

Expected excellent anti-inflammatory effect by decreasing the expression amount of IL-4 and IL-5.

A new compound prescription called PM014 is formed by adding a Stemonae Radix that has been known to be effective in inflammatory lung disease.

Classification PIPELINE Candidate material Preclinical Clinical trial New Drug approval Item authorization
1 2 3
Botanical medicine *COPD
Acute upper
  • Clinical Phase 3 completed
  • Item authorization in progress
  • Clinical Phase 2 costs 12 Billion
  • Clinical Phase 3 costs 200 Billion estimate

Preparation for approval of new drugs and items with domestic pharmaceutical companies (clinical 3-phase IND)

When entering the market with existing pharmaceutical companies, approval of their own products and marketing strategies are possible through entering the pharmaceutical companies

  • Sci Rep. 2017 Mar 21;7:45001 (IF: 4.259)

    Standardized Herbal Formula PM014 Inhibits Radiation-Induced Pulmonary Inflammation in Mice

  • J Ethnopharmacol. 2014 Aug 8;155(1):113-22 (IF: 2.981)

    The effects of the standardized herbal formula PM014 on pulmonary inflammation and airway responsiveness in a murine model of cockroach allergen-induced asthma

  • BMC Complement Altern Med. 2013 Sep 5;13:219 (IF: 2.981)

    The standardized herbal formula, PM014, ameliorated cigarette smoke-induced lung inflammation in a murine model of chronic obstructive pulmonary disease

  • J Ethnopharmacol. 2007 May 22;111(3):584-91 (IF: 2.981)

    Anti-ischemic effect of Aurantii Fructus on contractile dysfunction of ischemic and reperfused rat heart

  • Evid Based Complement Alternat Med. 2014;2014:189673 (IF: 1.740)

    Thirteen-Week Study of PM014 Subchronic Oral Toxicity in Rats

  • Evid Based Complement Alternat Med. 2012;2012:769830 (IF: 1.740)

    Herbal Formula, PM014, Attenuates Lung Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease

  • Biol Pharm Bull. 2006 Mar;29(3):483-8 (IF: 1.683)

    Effect of Acori Graminei Rhizoma on Contractile Dysfunction of Ischemic and Reperfused Rat Heart


Herbal medicine material for prevention and treatment of chronic obstructive pulmonary disease (Registration number: 1010188660000, 2010.11)

만성패쇄성 폐질환 COPD (PM014) 예시 이미지